Antiphospholipid syndrome in people 65 and older who had an ischemic stroke
A Prospective, Single-center Cohort Study to Determine the Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)
NA · CHU de Reims · NCT07163338
This study will test whether routine blood testing for antiphospholipid antibodies in people aged 65 and over hospitalized with ischemic stroke or TIA can identify previously unrecognized antiphospholipid syndrome.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | CHU de Reims (other) |
| Locations | 1 site (Reims) |
| Trial ID | NCT07163338 on ClinicalTrials.gov |
What this trial studies
The study will enroll patients aged 65 and older who are hospitalized for ischemic stroke or transient ischemic attack and collect blood samples for antiphospholipid antibody testing (anti-cardiolipin, anti-β2-glycoprotein I, and lupus anticoagulant). Researchers will determine the prevalence of positive antibody results in this older population and relate antibody presence to clinical features, stroke etiology, and short-term outcomes. Collected biological data will be compared with patients' clinical records to explore associations with arterial thrombosis and risk factors. Findings aim to inform whether routine screening in this age group uncovers treatable causes that change secondary prevention.
Who should consider this trial
Good fit: Ideal candidates are people aged 65 or older who are hospitalized for ischemic stroke or TIA, able to provide consent, and registered with the social security system.
Not a fit: Patients whose stroke cause is clearly explained by other factors (for example atrial fibrillation or advanced atherosclerosis) or who cannot undergo testing or long-term anticoagulation are less likely to gain direct benefit from this screening.
Why it matters
Potential benefit: If successful, the study could uncover previously unrecognized antiphospholipid syndrome in older stroke patients, which may lead to changes in long-term anticoagulation and potentially reduce recurrent thrombosis risk.
How similar studies have performed: Prior work shows antiphospholipid syndrome explains a notable share of ischemic strokes in younger patients, but systematic data and outcomes for routine screening in people aged 65 and over are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
inclusion criteria : * patients aged 65 and over during the inclusion phase * hospitalized for a TIA/ischemic stroke in neurology or internal medicine department during the inclusion phase * affiliated with social security system exclusion criteria : * patients under 65 years old * under legal guardianship, curatorship, or tutorship * incarcerated * under psychiatric care * admitted to a healthcare or social institution
Where this trial is running
Reims
- Damien JOLLY — Reims, France (RECRUITING)
Study contacts
- Study coordinator: Kévin DIDIER
- Email: kdidier@chu-reims.fr
- Phone: 03 26 83 24 44
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Antiphospholipid Syndrome, Antiphospholipid syndrome, antiphospholipid antibody syndrome, stroke, ischemic stroke